<p>英特格拉生命科学控股公司（NASDAQ:IART - 获取免费报告）在周五的午盘交易中股价下跌了 7.8%，原因是 Truist Financial 将其目标股价从 26.00 美元下调至 19.00 美元。Truist Financial 目前对该股票的评级为持有。英特格拉生命科学的股价最低曾达到 16.00 美元，最后交易价为 16.06 美元。在午盘交易中，共成交 178,151 股，较平均交易量 1,046,059 股下降了 83%。该股票此前收盘价为 17.42 美元。</p>
<p>获取 <strong>英特格拉生命科学</strong> 的提醒：</p>
<ul>
<li>3 只被低估的中型股即将上涨</li>
</ul>
<p>另外，Argus 在 3 月 31 日的报告中将英特格拉生命科学的股票评级从 “持有” 上调至 “买入”。三位分析师对该股票给予了卖出评级，五位给予了持有评级，两位给予了买入评级。根据 MarketBeat 的数据，英特格拉生命科学的平均评级为 “持有”，共识目标价为 22.71 美元。</p>
<p><strong>查看我们对英特格拉生命科学的最新分析</strong></p>
<h2>对英特格拉生命科学的对冲基金看法</h2>
<p>对冲基金和其他机构投资者最近增加或减少了对该股票的持仓。Principal Financial Group Inc.在第三季度将其在英特格拉生命科学的持仓增加了 18.7%。Principal Financial Group Inc.目前拥有 401,432 股该生命科学公司的股票，价值 7,294,000 美元，此前在上个季度购买了 63,266 股。挪威银行在第四季度购买了英特格拉生命科学的新股份，价值约为 8,967,000 美元。Nisa Investment Advisors LLC 在第四季度将其在英特格拉生命科学的持仓增加了 599.6%。Nisa Investment Advisors LLC 目前拥有 3,267 股该生命科学公司的股票，价值 74,000 美元，此前在上个季度增加了 2,800 股。PNC 金融服务集团在第四季度将其在英特格拉生命科学的持仓增加了 33.6%。PNC 金融服务集团目前拥有 19,755 股该生命科学公司的股票，价值 448,000 美元，此前在上个季度增加了 4,967 股。最后，Empowered Funds LLC 在第四季度收购了英特格拉生命科学的新股份，价值约为 180,000 美元。84.78% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>英特格拉生命科学的价格表现</h2>
<p>该公司的 50 日移动平均线为 22.46 美元，200 日移动平均线为 22.31 美元。该公司的速动比率为 0.73，流动比率为 1.20，债务与股本比率为 0.79。该股票的市值为 12.4 亿美元，市盈率为-177.42，市盈增长比率为 0.73，贝塔值为 1.24。</p>
<p>英特格拉生命科学（NASDAQ:IART - 获取免费报告）最近一次发布财报是在 2 月 25 日，生命科学公司报告该季度每股收益为 0.97 美元，超出分析师一致预期的 0.85 美元，超出 0.12 美元。该季度的营业收入为 4.4265 亿美元，而分析师预期为 4.4515 亿美元。英特格拉生命科学的净利润率为-0.42%，股本回报率为 12.35%。该公司的季度收入较去年同期增长了 11.5%。在去年同期，该公司每股收益为 0.89 美元。卖方分析师预测英特格拉生命科学控股公司今年将发布 2.45 美元的每股收益。</p>
<h2>英特格拉生命科学公司简介</h2>
<p>（获取免费报告）</p>
<p>英特格拉生命科学控股公司制造和销售用于神经外科、神经重症监护和耳鼻喉科的外科器械、神经外科产品和伤口护理产品。它分为两个部门，Codman Specialty Surgical 和 Tissue Technologies。该公司提供神经外科和神经重症监护产品，包括组织消融设备、硬膜修复产品、脑脊液管理设备、颅内监测设备和颅骨固定设备；以及外科头灯和仪器，以及售后服务。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过英特格拉生命科学</li>
<li>低市盈率增长股票：解锁投资机会</li>
<li>摩根大通是买入，如果你能承受波动性</li>
<li>什么是 S&amp;P/TSX 指数？</li>
<li>美国钢铁公司的崩溃：一个不容错过的买入机会</li>
<li>什么是纳斯达克证券交易所？</li>
<li>火箭实验室股票：经受风暴，是时候反弹了？</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在英特格拉生命科学吗？</h2>
<p>在考虑英特格拉生命科学之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议现在买入，以便在更广泛的市场注意到之前……而英特格拉生命科学并不在名单上。</p>
<p>虽然英特格拉生命科学目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得买入。</p>
<p>在这里查看这五只股票</p>

英特格拉生命科学

<p>英特格拉生命科学 (NASDAQ:IART) 的股价下跌了 7.8%，因 Truist Financial 将其目标价从 26.00 美元下调至 19.00 美元，并维持持有评级。该股最低交易价为 16.00 美元，交易量显著下降。尽管如此，Argus 将该股评级从持有上调至买入。目前，三位分析师给予卖出评级，五位给予持有评级，二位给予买入评级，平均目标价为 22.71 美元。公司报告的季度每股收益为 0.97 美元，超出预期，营收为 4.4265 亿美元，略低于预期</p>

<p>Integra LifeSciences Holdings Co. (NASDAQ:IART - Get Free Report)'s stock price fell 7.8% during mid-day trading on Friday after Truist Financial lowered their price target on the stock from $26.00 to $19.00. Truist Financial currently has a hold rating on the stock. Integra LifeSciences traded as low as $16.00 and last traded at $16.06. 178,151 shares changed hands during mid-day trading, a decline of 83% from the average session volume of 1,046,059 shares. The stock had previously closed at $17.42.</p>
<div class="lb-trans"><p>英特格拉生命科学控股公司（NASDAQ:IART - 获取免费报告）在周五的午盘交易中股价下跌了 7.8%，原因是 Truist Financial 将其目标股价从 26.00 美元下调至 19.00 美元。Truist Financial 目前对该股票的评级为持有。英特格拉生命科学的股价最低曾达到 16.00 美元，最后交易价为 16.06 美元。在午盘交易中，共成交 178,151 股，较平均交易量 1,046,059 股下降了 83%。该股票此前收盘价为 17.42 美元。</p>
</div><p>Get <strong>Integra LifeSciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>英特格拉生命科学</strong> 的提醒：</p>
</div><ul>
<li>3 Undervalued Midcaps Ready to Pop</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只被低估的中型股即将上涨</li>
</ul>
</div><p>Separately, Argus raised shares of Integra LifeSciences from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Monday, March 31st. Three analysts have rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, Integra LifeSciences has an average rating of &#34;Hold&#34; and a consensus target price of $22.71.</p>
<div class="lb-trans"><p>另外，Argus 在 3 月 31 日的报告中将英特格拉生命科学的股票评级从 “持有” 上调至 “买入”。三位分析师对该股票给予了卖出评级，五位给予了持有评级，两位给予了买入评级。根据 MarketBeat 的数据，英特格拉生命科学的平均评级为 “持有”，共识目标价为 22.71 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on Integra LifeSciences</strong></p>
<div class="lb-trans"><p><strong>查看我们对英特格拉生命科学的最新分析</strong></p>
</div><h2>Hedge Funds Weigh In On Integra LifeSciences</h2>
<div class="lb-trans"><h2>对英特格拉生命科学的对冲基金看法</h2>
</div><p>Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Principal Financial Group Inc. raised its position in shares of Integra LifeSciences by 18.7% during the 3rd quarter. Principal Financial Group Inc. now owns 401,432 shares of the life sciences company's stock worth $7,294,000 after purchasing an additional 63,266 shares during the last quarter. Norges Bank purchased a new stake in Integra LifeSciences during the 4th quarter worth approximately $8,967,000. Nisa Investment Advisors LLC raised its holdings in shares of Integra LifeSciences by 599.6% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company's stock valued at $74,000 after acquiring an additional 2,800 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in shares of Integra LifeSciences by 33.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 19,755 shares of the life sciences company's stock valued at $448,000 after acquiring an additional 4,967 shares in the last quarter. Finally, Empowered Funds LLC acquired a new stake in shares of Integra LifeSciences in the fourth quarter worth approximately $180,000. 84.78% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近增加或减少了对该股票的持仓。Principal Financial Group Inc.在第三季度将其在英特格拉生命科学的持仓增加了 18.7%。Principal Financial Group Inc.目前拥有 401,432 股该生命科学公司的股票，价值 7,294,000 美元，此前在上个季度购买了 63,266 股。挪威银行在第四季度购买了英特格拉生命科学的新股份，价值约为 8,967,000 美元。Nisa Investment Advisors LLC 在第四季度将其在英特格拉生命科学的持仓增加了 599.6%。Nisa Investment Advisors LLC 目前拥有 3,267 股该生命科学公司的股票，价值 74,000 美元，此前在上个季度增加了 2,800 股。PNC 金融服务集团在第四季度将其在英特格拉生命科学的持仓增加了 33.6%。PNC 金融服务集团目前拥有 19,755 股该生命科学公司的股票，价值 448,000 美元，此前在上个季度增加了 4,967 股。最后，Empowered Funds LLC 在第四季度收购了英特格拉生命科学的新股份，价值约为 180,000 美元。84.78% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Integra LifeSciences Price Performance</h2>
<div class="lb-trans"><h2>英特格拉生命科学的价格表现</h2>
</div><p>The company has a 50-day moving average of $22.46 and a 200 day moving average of $22.31. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. The stock has a market capitalization of $1.24 billion, a PE ratio of -177.42, a PEG ratio of 0.73 and a beta of 1.24.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均线为 22.46 美元，200 日移动平均线为 22.31 美元。该公司的速动比率为 0.73，流动比率为 1.20，债务与股本比率为 0.79。该股票的市值为 12.4 亿美元，市盈率为-177.42，市盈增长比率为 0.73，贝塔值为 1.24。</p>
</div><p>Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its earnings results on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, beating analysts' consensus estimates of $0.85 by $0.12. The business had revenue of $442.65 million during the quarter, compared to analysts' expectations of $445.15 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company's quarterly revenue was up 11.5% compared to the same quarter last year. During the same period in the prior year, the business earned $0.89 earnings per share. Sell-side analysts predict that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.</p>
<div class="lb-trans"><p>英特格拉生命科学（NASDAQ:IART - 获取免费报告）最近一次发布财报是在 2 月 25 日，生命科学公司报告该季度每股收益为 0.97 美元，超出分析师一致预期的 0.85 美元，超出 0.12 美元。该季度的营业收入为 4.4265 亿美元，而分析师预期为 4.4515 亿美元。英特格拉生命科学的净利润率为-0.42%，股本回报率为 12.35%。该公司的季度收入较去年同期增长了 11.5%。在去年同期，该公司每股收益为 0.89 美元。卖方分析师预测英特格拉生命科学控股公司今年将发布 2.45 美元的每股收益。</p>
</div><h2>Integra LifeSciences Company Profile</h2>
<div class="lb-trans"><h2>英特格拉生命科学公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.</p>
<div class="lb-trans"><p>英特格拉生命科学控股公司制造和销售用于神经外科、神经重症监护和耳鼻喉科的外科器械、神经外科产品和伤口护理产品。它分为两个部门，Codman Specialty Surgical 和 Tissue Technologies。该公司提供神经外科和神经重症监护产品，包括组织消融设备、硬膜修复产品、脑脊液管理设备、颅内监测设备和颅骨固定设备；以及外科头灯和仪器，以及售后服务。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Integra LifeSciences</li>
<li>Low PE Growth Stocks: Unlocking Investment Opportunities</li>
<li>JPMorgan is a Buy, if You Can Handle The Volatility</li>
<li>What is the S&amp;P/TSX Index?</li>
<li>United States Steel's Crash: An Unmissable Buying Opportunity</li>
<li>What is the NASDAQ Stock Exchange?</li>
<li>Rocket Lab Stock: Weathering the Storm, Time for a Comeback?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过英特格拉生命科学</li>
<li>低市盈率增长股票：解锁投资机会</li>
<li>摩根大通是买入，如果你能承受波动性</li>
<li>什么是 S&amp;P/TSX 指数？</li>
<li>美国钢铁公司的崩溃：一个不容错过的买入机会</li>
<li>什么是纳斯达克证券交易所？</li>
<li>火箭实验室股票：经受风暴，是时候反弹了？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Integra LifeSciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在英特格拉生命科学吗？</h2>
</div><p>Before you consider Integra LifeSciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑英特格拉生命科学之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Integra LifeSciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议现在买入，以便在更广泛的市场注意到之前……而英特格拉生命科学并不在名单上。</p>
</div><p>While Integra LifeSciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然英特格拉生命科学目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得买入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

英特格拉生命科学（纳斯达克股票代码：IART）股价在分析师下调评级后下跌了 7.8%